Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine and Attentional Brain Networks
NCT05320120Phase 1Completed
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of esketamine in major depressive disorder (MDD) (2 arms). Primary endpoint: Blood Oxygen Level Dependent response at 2 weeks. Started Jun 2022; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05320120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320120.